Bio Net Debt vs Accounts Payable Analysis

BGT Stock   0.04  0  2.33%   
Bio Gene financial indicator trend analysis is way more than just evaluating Bio Gene Technology prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Gene Technology is a good investment. Please check the relationship between Bio Gene Net Debt and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Gene Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Debt vs Accounts Payable

Net Debt vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Gene Technology Net Debt account and Accounts Payable. At this time, the significance of the direction appears to have pay attention.
The correlation between Bio Gene's Net Debt and Accounts Payable is -0.97. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Bio Gene Technology, assuming nothing else is changed. The correlation between historical values of Bio Gene's Net Debt and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Bio Gene Technology are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Debt i.e., Bio Gene's Net Debt and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.97
Relationship DirectionNegative 
Relationship StrengthSignificant

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Accounts Payable

An accounting item on the balance sheet that represents Bio Gene obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bio Gene Technology are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Bio Gene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Gene Technology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Gene Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Selling General Administrative is likely to gain to about 1.5 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 2.2 M in 2024.
 2021 2022 2023 2024 (projected)
Reconciled Depreciation43.5K45.3K38.4K37.4K
Interest Income52.9K86.0K87.0K60.7K

Bio Gene fundamental ratios Correlations

0.830.751.00.730.81-0.98-0.431.00.65-0.331.00.540.340.690.751.00.630.710.810.65-0.740.94-0.750.690.13
0.830.970.80.810.55-0.79-0.710.810.36-0.10.810.730.560.860.890.840.340.870.540.77-0.880.83-0.880.850.13
0.750.970.710.860.55-0.71-0.730.720.3-0.080.720.70.480.90.920.760.280.850.550.82-0.850.76-0.850.910.14
1.00.80.710.70.8-0.99-0.41.00.64-0.331.00.510.30.650.711.00.620.690.80.61-0.720.94-0.720.650.13
0.730.810.860.70.62-0.69-0.80.690.310.050.690.80.370.90.780.730.270.940.60.9-0.910.69-0.910.920.43
0.810.550.550.80.62-0.77-0.30.790.88-0.440.790.460.30.60.670.80.860.511.00.68-0.540.69-0.550.610.21
-0.98-0.79-0.71-0.99-0.69-0.770.32-0.99-0.650.43-0.99-0.47-0.28-0.63-0.7-0.98-0.63-0.66-0.77-0.570.66-0.970.67-0.62-0.01
-0.43-0.71-0.73-0.4-0.8-0.30.32-0.390.0-0.48-0.39-0.88-0.57-0.84-0.63-0.440.02-0.89-0.28-0.830.91-0.330.91-0.84-0.66
1.00.810.721.00.690.79-0.99-0.390.63-0.341.00.50.30.640.711.00.610.680.790.59-0.710.95-0.720.640.1
0.650.360.30.640.310.88-0.650.00.63-0.70.630.310.370.310.470.631.00.250.880.43-0.260.59-0.260.28-0.11
-0.33-0.1-0.08-0.330.05-0.440.43-0.48-0.34-0.7-0.340.180.020.04-0.21-0.32-0.710.13-0.460.01-0.21-0.47-0.220.080.72
1.00.810.721.00.690.79-0.99-0.391.00.63-0.340.50.30.640.711.00.610.680.790.59-0.710.95-0.720.640.1
0.540.730.70.510.80.46-0.47-0.880.50.310.180.50.790.850.710.540.30.910.430.85-0.880.48-0.880.760.51
0.340.560.480.30.370.3-0.28-0.570.30.370.020.30.790.60.570.330.370.570.280.56-0.530.29-0.530.420.25
0.690.860.90.650.90.6-0.63-0.840.640.310.040.640.850.60.90.690.280.930.580.93-0.880.64-0.890.940.42
0.750.890.920.710.780.67-0.7-0.630.710.47-0.210.710.710.570.90.750.450.760.670.81-0.760.73-0.760.850.1
1.00.840.761.00.730.8-0.98-0.441.00.63-0.321.00.540.330.690.750.610.720.80.65-0.750.95-0.760.70.13
0.630.340.280.620.270.86-0.630.020.611.0-0.710.610.30.370.280.450.610.230.860.4-0.230.57-0.240.25-0.13
0.710.870.850.690.940.51-0.66-0.890.680.250.130.680.910.570.930.760.720.230.490.9-0.960.67-0.960.90.47
0.810.540.550.80.61.0-0.77-0.280.790.88-0.460.790.430.280.580.670.80.860.490.66-0.520.69-0.530.60.18
0.650.770.820.610.90.68-0.57-0.830.590.430.010.590.850.560.930.810.650.40.90.66-0.860.54-0.860.950.46
-0.74-0.88-0.85-0.72-0.91-0.540.660.91-0.71-0.26-0.21-0.71-0.88-0.53-0.88-0.76-0.75-0.23-0.96-0.52-0.86-0.661.0-0.89-0.51
0.940.830.760.940.690.69-0.97-0.330.950.59-0.470.950.480.290.640.730.950.570.670.690.54-0.66-0.670.6-0.1
-0.75-0.88-0.85-0.72-0.91-0.550.670.91-0.72-0.26-0.22-0.72-0.88-0.53-0.89-0.76-0.76-0.24-0.96-0.53-0.861.0-0.67-0.89-0.52
0.690.850.910.650.920.61-0.62-0.840.640.280.080.640.760.420.940.850.70.250.90.60.95-0.890.6-0.890.41
0.130.130.140.130.430.21-0.01-0.660.1-0.110.720.10.510.250.420.10.13-0.130.470.180.46-0.51-0.1-0.520.41
Click cells to compare fundamentals

Bio Gene Account Relationship Matchups

Bio Gene fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets6.6M5.0M7.3M3.8M3.2M5.0M
Other Current Liab266.4K504.6K790.2K455.2K298.7K384.0K
Total Current Liabilities412.0K592.7K1.0M573.9K345.9K466.3K
Total Stockholder Equity6.0M4.2M6.3M3.2M2.8M4.5M
Net Tangible Assets4.6M5.7M3.9M6.0M6.9M3.6M
Property Plant And Equipment Net37.0K22.7K23.0K14.6K19.0K26.0K
Net Debt(5.5M)(3.9M)(6.3M)(3.0M)(2.2M)(2.3M)
Retained Earnings(9.5M)(11.7M)(14.5M)(17.4M)(19.6M)(18.7M)
Cash5.5M3.9M6.3M3.0M2.2M4.1M
Non Current Assets Total387.9K336.7K300.1K254.8K222.2K271.5K
Non Currrent Assets Other(387.9K)(336.7K)(300.1K)(254.8K)203.2K213.3K
Cash And Short Term Investments5.5M3.9M6.3M3.0M2.2M4.1M
Common Stock Shares Outstanding119.4M137.2M153.3M167.8M185.8M141.8M
Liabilities And Stockholders Equity6.6M5.0M7.3M3.8M3.2M5.0M
Other Stockholder Equity950.0K863.3K1.2M818.5K941.2K715.1K
Total Liab567.3K754.6K1.0M613.9K368.4K601.7K
Total Current Assets6.2M4.7M7.0M3.6M2.9M4.6M
Accumulated Other Comprehensive Income950.0K863.3K1.2M1.1M907.0K743.2K
Intangible Assets351.0K314.0K277.1K240.1K203.2K252.5K
Common Stock11.8M14.5M15.1M19.5M21.5M13.0M
Property Plant Equipment37.0K22.7K23.0K14.6K16.8K26.6K
Net Receivables483.0K523.8K438.2K445.6K524.0K401.8K
Accounts Payable134.0K88.1K219.0K118.7K47.2K44.9K
Non Current Liabilities Total155.3K161.9K25.5K40.0K22.5K21.4K
Inventory102.6K132.9K148.8K70.2K80.7K84.8K
Short Term Investments4.3M5.3M74.2K1.5M1.4M2.6M
Net Invested Capital6.0M4.2M6.3M3.2M2.8M4.4M
Property Plant And Equipment Gross32.7K37.0K52.2K50.5K56.2K47.9K
Net Working Capital5.8M4.1M6.0M3.0M2.6M4.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bio Stock Analysis

When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.